No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
AU Stock MarketDetailed Quotes
PTX Prescient Therapeutics Ltd
- 0.042
- +0.001+2.44%
20min DelayMarket Closed Dec 13 14:02 AET
33.82MMarket Cap-4.20P/E (Static)
0.043High0.041Low168.98KVolume0.042Open0.041Pre Close7.05KTurnover0.07252wk High0.03%Turnover Ratio805.32MShares0.03752wk Low-0.01EPS TTM27.87MFloat Cap78409.237Historical HighLossP/E (Static)663.52MShs Float0.022Historical Low-0.01EPS LYR4.88%Amplitude--Dividend TTM1.91P/B1Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Prescient Therapeutics CEO Yatomi-Clarke Steps Down; Will Remain Available as a Consultant
Prescient Therapeutics "an ASX-listed Oncology Drug Developer With a Big FY25 Ahead", Says Pitt Street Research
Prescient Therapeutics Ltd: Appendix 4E and 2024 Annual Report
Prescient Therapeutics Refines Phase 2 PTX-100 Trial Design for Greater Success
Prescient Therapeutics Appoints Accomplished Medical Professional Dr Gavin Shepherd as a Director
We're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash Wisely
Heat List
AU
Overall
Symbol
Price
% Chg
No Data